KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Depreciation & Amortization (CF) (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Depreciation & Amortization (CF) for 15 consecutive years, with $25.0 million as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) rose 32.75% to $25.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $91.6 million through Dec 2025, up 13.86% year-over-year, with the annual reading at $91.6 million for FY2025, 13.86% up from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $25.0 million at Supernus Pharmaceuticals, up from $24.8 million in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $25.0 million in Q4 2025, with the low at $6.6 million in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $18.7 million, with a median of $20.7 million recorded in 2023.
  • Peak annual rise in Depreciation & Amortization (CF) hit 280.6% in 2021, while the deepest fall reached 14.89% in 2021.
  • Over 5 years, Depreciation & Amortization (CF) stood at $12.7 million in 2021, then surged by 64.07% to $20.8 million in 2022, then rose by 3.97% to $21.7 million in 2023, then fell by 13.06% to $18.8 million in 2024, then surged by 32.75% to $25.0 million in 2025.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $25.0 million, $24.8 million, and $21.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.